August 09, 2016
A shareholder in CTI Biopharma Corp. on Tuesday brought a derivative suit in Washington federal court accusing the company's executives of withholding information about patient deaths during clinical trials for its myelofibrosis drug pacritinib, causing stock prices to plummet when the U.S. Food and Drug Administration stopped the trials.